Peptide · Agonist of parathyroid hormone (PTH) · developed by Entera Bio
Teriparatide (PTH) is a parathyroid hormone peptide given by subcutaneous injection. It acts on the parathyroid hormone system, which modulates blood calcium and phosphate concentrations.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03516773 | Phase 2 | Hypoparathyroidism | Completed | ENTX |
| NCT02571140 | Phase 1 | Drug Safety and Bioavailability | Completed | ENTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Drug Safety and Bioavailability
Updated Nov 15, 2026. Something wrong or missing? Report it on the ENTX page.
See ENTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ENTX catalysts and pipeline →